Taselisib (** Generic name only (development discontinued) **)

Other Medications

EU Not submitted to EMA ES Not available 1 Clinical Trials

Description

Taselisib is an investigational drug that was studied in clinical trials for certain types of advanced cancers, including colorectal cancer. It is currently not approved for use in colorectal cancer. Clinical trials, like NCT02465060, investigated taselisib in patients whose tumors had specific genetic changes, such as a MET mutation. These trials aimed to see if taselisib could shrink tumors or slow their growth in these patients. Taselisib targets a specific protein involved in cell signaling pathways that can contribute to cancer growth. The development of taselisib has been discontinued.

Mechanism of Action

Taselisib is a phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor. It works by blocking the activity of the PI3Kδ enzyme, which is involved in signaling pathways that promote cell growth, survival, and proliferation. By inhibiting PI3Kδ, taselisib aims to disrupt these pathways and potentially stop or slow down the growth of cancer cells.

Side Effects

As an investigational drug The full range of side effects for taselisib is still being evaluated. Clinical trials reported side effects such as diarrhea Fatigue Nausea Decreased appetite Vomiting And rash. More specific side effect data related to CRC trials is limited due to discontinued development. Patients participating in trials were closely monitored for adverse events.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT02465060 Phase 2
Active, not recruiting
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
United States, Guam, Puerto Rico

Quick Info

Brand Name** Generic name only (development discontinued) **
CategoryOther Medications
EU EMA StatusNot submitted to EMA
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
781 trials
Leucovorin
Other Medications
641 trials
Paclitaxel
Other Medications
54 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials
Trifluridine
Other Medications
48 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.